Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity  by Bello, Martiniano et al.
Biochemical Pharmacology 90 (2014) 145–158Structural and energetic analysis to provide insight residues of
CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation
selectivity
Martiniano Bello *, Jessica E. Mendieta-Wejebe, Jose´ Correa-Basurto *
Laboratorio de Modelado Molecular, Bioinforma´tica y Disen˜o de Fa´rmacos de la Escuela Superior de Medicina, Instituto Polite´cnico Nacional,
Plan de San Luis y Dı´az Miro´n s/n, Casco de Santo Toma´s, Me´xico, Distrito Federal 11340, Mexico
A R T I C L E I N F O
Article history:
Received 13 March 2014
Accepted 25 April 2014
Available online 2 May 2014
Keywords:
Drug metabolism
CYP450 enzymes
Molecular dynamics simulations
Molecular mechanics generalized born
surface area
A B S T R A C T
Docking and molecular dynamics (MD) simulation have been two computational techniques used to gain
insight about the substrate orientation within protein active sites, allowing to identify potential residues
involved in the binding and catalytic mechanisms. In this study, both methods were combined to predict
the regioselectivity in the binding mode of valproic acid (VPA) on three cytochrome P-450 (CYP) isoforms
CYP2C9, CYP2C11, and CYP2E1, which are involved in the biotransformation of VPA yielding reactive
hepatotoxic intermediate 2-n-propyl-4-pentenoic acid (4nVPA). There are experimental data about
hydrogen atom abstraction of the C4-position of VPA to yield 4nVPA, however, there are not structural
evidence about the binding mode of VPA and 4nVPA on CYPs. Therefore, the complexes between these
CYP isoforms and VPA or 4nVPA were studied to explore their differences in binding and energetic
stabilization. Docking results showed that VPA and 4nVPA are coupled into CYPs binding site in a similar
conformation, but it does not explain the VPA hydrogen atom abstraction. On the other hand, MD
simulations showed a set of energetic states that reorient VPA at the ﬁrst ns, then making it susceptible to
a dehydrogenation reaction. For 4nVPA, multiple binding modes were observed in which the different
states could favor either undergo other reaction mechanism or ligand expulsion from the binding site.
Otherwise, the energetic and entropic contribution point out a similar behavior for the three CYP
complexes, showing as expected a more energetically favorable binding free energy for the complexes
between CYPs and VPA than with 4nVPA.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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Valproic acid (VPA, Fig. 1) is an important antiepileptic drug
that has been widely used in the management of various types of
seizure disorders [1]. Although VPA is considered a relatively safe
drug, in some occasions, it may associate with severe and
sometimes fatal liver injury [2]. Although the mechanism of
VPA hepatotoxicity is not understood so far, there are multiple
factors that could contribute to the toxicity, including (1)
formation of reactive metabolites of VPA [3] and the subsequentAbbreviations: CYP, cytochrome P-450; CYP2C9, cytochrome P-450 C9; CYP2C11,
cytochrome P-450 C11; CYP2E1, cytochrome P-450 E1; MD, molecular dynamics;
MM-GBSA, molecular mechanics generalized born surface area; PDB, protein data
bank; RMSD, root mean square deviation; 3D, three-dimensional; VPA, valproic
Acid; 4nVPA, 2-n-propyl-4-pentenoic acid; VMD, visual molecular dynamics.
* Corresponding authors.
E-mail addresses: mbellor@ipn.mx, bellomartini@gmail.com (M. Bello), jcorrea-
b@ipn.mx, corrjose@gmail.com (J. Correa-Basurto).
http://dx.doi.org/10.1016/j.bcp.2014.04.016
0006-2952/ 2014 The Authors. Published by Elsevier Inc. This is an open access articcovalent binding to cellular proteins [4–6], and (2) development of
oxidative stress [7].
In the course of the characterization of the metabolism of VPA,
it was discovered that there were multiple metabolic pathways
involved in its biotransformation which give rise to more than 50
known metabolites of the parent drug [8]. However, from these
multiple pathways, the oxidative metabolism of VPA by cyto-
chrome P450 (CYP) constitutes a minor metabolic pathway, but it
represents the one which generates the hepatotoxic metabolite 2-
n-propyl-4-pentenoic acid (4nVPA) in liver microsomes from rats,
mice, rabbits and humans [9]. Experiments using deuterated
analogs of VPA to obtain evidence about the dehydrogenation
reaction demonstrated that this reaction proceeds via hydrogen
atom abstraction of the C4-position [9]. The metabolism of VPA to
4nVPA represents a dehydrogenation reaction of a sp3 hybridized
center, which is not adjacent to any sp2 hybridized carbon center.
The metabolite arises by either abstraction of a second hydrogen
atom by the Fe(IV)–OH intermediate and subsequent collapse
of the diradical or via abstraction of an electron and deprotonationle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
OOH
C5
C4
OOH
Fig. 1. Chemical structures of VPA (left) and 4nVPA (right).
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although this kind of biochemical reaction is unusual in nature;
there are several cases where this reaction has been observed [10–
16].
CYP is a superfamily of cysteinato-heme enzymes [10,17]. Its
active site contains a heme, which is deeply buried inside the
protein at the bottom of a large, internal binding cavity. Heme unit
consists of an iron protoporphyrin IX complex with a cysteine (Cys)
residue as the proximal axial ligand. The active catalytic species,
with a Fe(IV)-oxo moiety, is commonly denoted as Compound I.
These enzymes are potent oxidants involved in oxidizing reactions
such as the hydroxylation of saturated carbon-hydrogen bonds, the
epoxidation of double bonds, the oxidation of heteroatoms,
dealkylation reactions, and oxidations of aromatics using dioxygen
to catalyze a great variety of stereospeciﬁc and regioselective
processes of oxygen insertion into a variety of organic compounds,
both of endogenous (such as steroids) and exogenous (xenobiotics)
origins [18–23]. Furthermore, CYP enzymes can also catalyze the
dehydrogenation of some organic molecules instead of carrying
out the oxygenation of the substrate as observed for VPA and other
organic molecules [24]. In this manner, CYP converts all the
dioxygen into water and generates an oleﬁn, thus exhibiting a
mixed function as an oxidase-dehydrogenase enzyme.
The CYP enzymes share common structural characteristics such
as a common overall fold despite less than 20% sequence identity
across the CYP gene superfamily [23]. In recent years, the
elucidation of several complexes of CYP crystal structures has
provided further insight into the important structural aspects of
these critical interactions, pointing out that steric and electronic
parameters of the enzyme active site residues facilitate dehy-
dratation or dehydrogenation reactions by positioning the
substrate and/or stabilizing transition states [25,26]. On the other
hand, although we have a general understanding about how 4nVPA
is formed [9], the precise mechanisms or factors that direct
dehydrogenation versus oxygenation are not well understood.
Because human CYP2C9, CYP2E1 and rat CYP2C11 have been
reported as VPA metabolizing in liver microsomes and also
involved in 4nVPA formation [27], elucidating the factors that
control its dehydrogenation is crucial to the design of analog drugs
with reduced risks of metabolic activation.
Molecular models are valuable tools for studying substrate
orientation within the CYP active site [28–31]. Nevertheless, the
predictive power of these procedures is highly dependent on
several factors, such as the accurate of the three-dimensional (3D)
structure used as target [32,33] and the force ﬁeld parameters for
accurately determining the interactions between a compound and
its target [34]. Bioinformatics methods have been widely used to
predict ligand conformation into CYPs binding sites [13,35]. Moore
et al. performed docking studies to model the metabolism of
raloxifene, a CYP3A4-mediated dehydrogenated substrate [13].
Molecular docking is a method that predicts the binding mode of a
ligand to a protein, and has been extensively used in rational
design of drug [36–38]. However, some researcher have mentioned
that the conformations obtained through docking procedures need
to be examined by molecular dynamic (MD) simulations [39,40].
Therefore, in order to propose a plausible binding conformation
between VPA or 4nVPA and CYPs that would allow to explain the
binding orientation of both ligands into CYPs binding site as to be
susceptible to undergo a dehydrogenation reaction, we carried outautomatic molecular docking using AutoDock software. Afterward,
the dynamic stability of these complexes conformations were
further analyzed using MD simulations, together with binding free
energy estimation using the Molecular Mechanics Generalized
Born Surface Area (MMGBSA) method.
To develop this study, we utilized two X-ray crystal structures
of human beings (CYP2C9 and CYP2E1) and a model from rat
(CYP2C11), which was obtained through homology modeling
procedures. Structural analysis shows that CYP2C9, CYP2C11, and
CYP2E1 share a similar overall folding structure (Fig. 2A), where
the substrate binding cavity is formed by similar secondary
structure elements: helices I, F, G, and F–G, B–C loops (Fig. 2B).
These CYPs structures were chosen because it has been reported
that both human enzymes catalyze the dehydrogenation of VPA
[41–43], whereas that CYP2C11 is one of the most active and
versatile CYP in rat liver microsomes [44–47] and the one used
widely in our laboratory to evaluate the VPA metabolism. Thus, in
overall our aim in this study is to determine whether or not the
dehydrogenation mechanism was consistent among CYP enzymes
or differences were possible among the isoforms. Finally, our
results demonstrate the utility of these combined techniques in
evaluating the intricate interactions between dehydrogenated
substrates and CYP enzymes.
2. Methods
2.1. Homology modeling of CYP2C11
Since the crystal structure of CYP2C11 is not available so far in
the Protein Data Bank (PDB), the 3D model of CYP2C11 used in the
present contribution was constructed based on a homology
modeling method using the known 3D structures of CYP2C9
(1R9O) and CYP2E1 (3KOH) as templates, and under the following
procedure. First, we explored the NCBI protein data base [http://
www.ncbi.nlm.nih.gov/sites/entrez] to search the amino acid
sequences of rat CYP2C11 (Swiss-prot entry code: P08683). The
ClustalW program version 2.0 [48] was used to identify similarity
of this sequence to other CYP structures, and the I-TASSER server
[49] was used to generate the 3D model. Once obtained the latter,
this was minimized using MD simulations and its dihedral angles
were validated by checking its Ramachandran map. Afterward, a
protein sequence alignment among the CYP2C11 sequence, and
those of templates (CY2C9 (1R9O) and CYP2E1 (3KOH)) was
performed using ClustalW program [48] to evaluate the percentage
of identity among the three CYP sequences, whereas that the level
of conservation for each residue was calculated using PRALINE
server [50].
2.2. Automated docking
AutoDock version 4.0.1 [51] was used to perform the automated
docking studies between VPA or 4nVPA versus CYPs. Both
substrates were treated as ﬂexible ligands by modifying their
rotatable torsions, but CYP2C9 (Fig. 2C), CYP2C11 and CYP2E1
(Fig. 2D and E) template were considered to be a rigid protein. 3D
coordinates of the CYP2C9 and CYP2E1 structures 1R9O and 3KOH,
respectively, were acquired from the PDB, whereas CYP2C11 was
constructed using homology modeling procedures (see Section
2.1). X-ray structures were cleaned of both water molecules and
co-crystallized ligands.
The substrate structures were drawn using the Isis/Draw
program [52], and then were converted to a 3D format using
WebLab Viewer and Molekel Visualization Package [53,54]. A
geometric pre-optimization was carried out by using HyperChem
6.0 [55]. The minimum energy structure of the ligands was
obtained using a semi-empical method at the AM1 level by
Fig. 2. Superposition of the overall folding and molecular models of VPA and 4nVPA in the substrate binding site of CYP2C9, CYP2C11, and CYP2E1 predicted by AutoDock
version 4.0.1. Folding structures (A) and substrate binding sites (B) of CYP2C9 (white), 2C11 (green), and 2E1 (orange), structures are shown in cartoon representations, and
the heme group is represented with white spheres. The RMSD values between CYP2C9 and CYP2C11 or CYP2E1 were 1.692 or 1.578, respectively. VPA or 4nVPA was docked
into CYPs, and a representative conformation from the largest and lowest-energy cluster, predicted dehydrogenation from docking between VPA (cyan stick representation)
or 4nVPA (yellow stick representation) and CYP2C9 (C); that from docking with CYP2C11 is shown in panel (D), and that from docking with CYP2E1 is depicted in panel (E).
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formalism) and all rotatable bonds of the ligands as well as the
Kollmand charges for all the protein atoms were assigned by
AutoDock Tools [51].
To deﬁne the binding sites in which the substrates moved,
AutoGrid version 3.06 [51] was used. First, rectangular grid boxes
were constructed over all proteins (47.798, 34.060 and 54.683 A˚3,
for CYP2C9), (57.950, 57.040 and 57.940 A˚3, for CYP2C11) and
(65.660, 67.520 and 62.560 A˚3, for CYP2E1) with the grid points
separated by 0.375 A˚, centered on the ligand binding pocket (upper
iron atom at 1.9 A˚). The box size was decreased to force the ligands
to enter at the active site.
All docking simulations were carried out by using the hybrid
Lamarckian Genetic Algorithm, with an initial population of 100
randomly placed individuals and a maximum number of 1.0  107
energy evaluations. The resulting docked orientations within a
root-mean square deviation (RMSD) of 0.5 A˚ were clustered
together. The lowest energy cluster returned by AutoDock for
each compound was used for further analysis. All other parameters
were maintained at their default settings.
Finally, to determine whether a ligand could be recognized by
the proteins, one ligand was ﬁrst docked following the conditions
mentioned earlier, using the box size 120  120  120 A˚3. Then, its
coordinates were pasted to proteins PDB structures, obtaining a
protein-ligand complex.
2.3. Molecular dynamics (MD) simulations
A series of MD simulations were carried out for all complexes
obtained under docking procedures (see Section 2.2). Thesimulations and the analysis of the trajectories were performed
with Amber 12 package [57] using the FF99SB force ﬁeld [58].
Complexes were constructed using the Leap module, minimized
by the sander module, and the ‘‘pmemd’’ module was used for
MD simulations. The ligand parameters were estimated with the
antechamber module, based on the general AMBER force ﬁeld
(GAFF) [59], followed by ab initio optimization of ligands at the
AM1-BCC level [60]. The missing force ﬁeld parameters for
Heme (all-atom) group were taken from the AMBER parameter
database [61]. Cl ions were placed by Leap to neutralize the
positive charges of areas around the complex models at pH 7. A
rectangular-shaped box of water was constructed using the
TIP3P water model [62], with a margin of 12.0 A˚ in each
direction from the solute. The systems were then equilibrated by
a 500 ps of energy minimization with position restraints on the
protein and ligand to allow for relaxation of the solvent
molecules. The equilibration run was followed by a 50 ns MD
run without position restraints under periodic boundary
conditions.
The non-bonded list was generated using an atom-based
cutoff of 8.0 A˚. The electrostatic term was described with the
particle mesh Ewald algorithm [63]. The time step of the MD
simulations was set to 2.0 fs, and the SHAKE algorithm [64]
was used to constrain bond lengths at their equilibrium
values. Temperature and pressure were maintained using the
weak-coupling algorithm [65] with coupling constants tT and
tP of 1.0 and 0.2 ps, respectively (300 K, 1 atm). Coordinates
were saved for analyses every 1 ps. Analysis of the trajectories
was performed using AMBER analysis tools [57] and PyMOL
[66].
Fig. 3. Average conformations of CYP2C9–VPA, CYP2C9–4nVPA complex and the crystallographic structure of the CYP2C9–FLP complex. (A) Structural superposition of the
average conformations of CYP2C9–VPA, CYP2C9–4nVPA, and CYP2C9–FLP complex. (B) Residues constituting the hydrophobic cleft (V113, L201, N204, I205, L208, V292, G296, A297,
E300, and L366), narrow solvent channel (L102 and R108), and the Phe cluster (F100, F114 and F476), are rendered as blue, orange and red stick representations, respectively.
Residues stabilizing the VPA (C) or 4nVPA (D) conformation within 4 A˚ are depicted in green stick representation. VPA, 4nVPA, and FLP are shown in cyan, yellow, and blue ball
and stick representations, respectively. Oxygen, nitrogen, and FE are colored red, blue, and cyan. For reference, the heme is shown as ball and stick ﬁgure colored white, and
structural elements building the folding and substrate binding cavity are rendered as cartoon ﬁgures. The average conformations were calculated over the ﬁnal 40-ns of the
MD simulations.
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Binding free energies were calculated using MM-GBSA
approach supplied with Amber 12 package [57], using a salt
concentration of 0.1 M, and the Born implicit solvent model of 2
(igb = 2) [67]. For the CYP2C9–VPA (Fig. 3C) and CYP2C9–4nVPA
(Fig. 3D) complexes, the binding free energy was calculated
using 400 snapshots of each model at time intervals of 100 ps
from the last 40-ns production runs. For the four CYP2C11–VPA
conformations present during the last 40-ns of MD simulations,
the binding free energies were calculated using 150 snapshots
for CYP2C11–VPAc (Fig. 4C, 10–25 ns), 50 snapshots CYP2C11–
VPAd–e (Fig. 4D and E, 25–30 ns), and 200 snapshots CYP2C11–
VPAf (Fig. 4F, 30–50 ns). From the two CYP2C11–4nVPA
conformations present during the last 40-ns of MD simulations,
the binding free energy for the most representative conforma-
tion was calculated using 350 snapshots (Fig. 4G, 10–45 ns).
From the three CYP2E1–VPA (depicting a superposition of VPA
and 4nVPA, Fig. 5A and B) conformations present during de MD
simulation, the binding free energy for the most representative
conformation was calculated using 400 snapshots (Fig. 5C, 10–
50 ns). For the CYP2E1–4nVPA conformations showed during the
simulation, the binding free energy for the most predominant
conformation was estimated using 400 snapshots (Fig. 5G,10–50 ns). The MM-GBSA method can be conceptually summa-
rized as:
DGbind ¼ DGcomplex  DGreceptorDGligand (1)
DGbind ¼ DH  T DS (2)
where DGcomplex, DGreceptor, and DGligand are the free energies of
complex, CYPs and VPA or 4nVPA, respectively. DH of the system
is composed of the enthalpy changes in the gas phase upon
complex formation (DEMM) and the solvated free energy
contribution (DGsol), while T DS refers to the entropy contribu-
tion to the binding. Eq. (2) can be then approximated as shown in
the following equation:
DGbind ¼ DEMM þ DGsol  T DS (3)
DEMM þ DEvdw þ DEels þ DEint (4)
DGsol ¼ DGels;sol þ DGnonpolar;sol (5)
where DEMM is the summation of the van der Waals (DEvdw),
electrostatic energies (DEele) and torsional angle energies (DEint).
Fig. 4. Average conformations of VPA or 4nVPA into the active site of CYP2C11. (A) Structural superposition of the average conformations of CYP2C11–VPA, and CYP2C11–
4nVPA complex. (B) Residues constituting the hydrophobic cleft (I113, T292, D293, G296, A297, E300, T301, and L366), narrow solvent channel (N202, and M198), and the Phe cluster
(F100, F114, F205, F208, F237, and F476), are rendered as blue, orange and red stick representations, respectively. Conformation presented during the ﬁrst 25-ns (C), two
conformations available after 25-ns and until the 30-ns ((D) and (E)), and the conformation presented from 30 to 50 ns (F). (G) The ﬁrst and the most representative CYP2C11–
4nVPA conformation present from 10 to 45 ns, and the second conformation present during the last 5 ns (H).
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can be computed as the summation of an electrostatic
component (DGele,sol) and a non-polar component (DGnon-
polar,sol), and T DS the contribution from the conformational
entropy.
Entropic contributions were evaluated using MMPBSA.py
module implemented in Amber Tools 1.5 [57], only 20 snapshots
taken at time intervals of 200 ps were chosen. Because of the large
memory demanding for this calculation, we did not use the entire
system, therefore, an approach reported elsewhere [68], which
only residues with any atom within 8 A˚ of the ligand in the last
conformation (truncated system) were considered to perform the
entropy calculation.3. Results
3.1. Sequence alignment results
The sequence alignment among CYP2C11 sequence and those of
the two templates (CYP2C9, 1R9O) and (CYP2E1, 1KOH) was
carried out, and the protein sequence alignment is shown in Fig. 6.
This analysis shows that the amino acid sequence of the aligned
protein templates of chain A of CYP2C9 (1R9O) exhibited the
highest percentage of identity with that of CYP2C11 in the range of
74.42%. The percentage of identity between the chain A of CYP2C9
(1R9O) and the chain A of CYP2E1 (1KOH) was 58.4%, whereas the
percentage of identity between CYP2C11 sequence (Swiss-prot
Fig. 5. Average conformations of VPA and 4nVPA into the active site of CYP2E1. (A) Structural superposition of the average conformations of CYP2C11–VPA, and CYP2C11–
4nVPA complex. (B) Residues constituting the hydrophobic cleft (I115, E302, A299, T303, L363, V364, and L368), narrow solvent channel (V364 and F478), and the Phe cluster (F106,
F116, F207, F298, and F478), are rendered as blue, orange and red stick representations, respectively. Two VPA conformations presented during the ﬁrst 3-ns ((C) and (D)), and the
third VPA conformation presented after 3-ns and until the end of the MD simulation (E). Conformation between 4nVPA and CYP2E1 during the ﬁrst 10-ns (F), and the most
representative conformation present after this time and until the end of the MD simulation (G).
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Furthermore, this analysis shows that several residues lining the
substrate binding site are conserved or highly conserved among
the three CYPs: R97, I/V113, F114, N204, S209, N217, N238, T301, D293,
A297, E300, T304, L361, L366,P367, and F476, that are R100, I115, F116, N206,
S211, N219, N240, T303, D295, A299, E302, T306, L363, L368, P369, and F478
in CYP2E1 (Fig. 6). Whereas some residues are only conserved
between two CYPs: between CYP2C9 and CYP2C11 (F100), CYP2C11
and CYP2E1 (F205/F207) or CYP2C9 and CYP2E1 (L208/L210). Overall,
these results show that despite the low sequence identity (20%)
between some CYPs [23], the three CYPs studied here possess a
relative high level of sequence identity which is present not only
along their overall folding structures but also at the substrate
binding sites.3.2. Docking results
It has been reported that CYP2C9 and CYP2C11 possess activity
toward VPA and although 4nVPA only constitutes one of the
multiple secondary metabolites product of VPA metabolism, is the
one with hepatotoxic properties and the main product of its
dehydrogenation pathway [9]. On the other hand, despite CYP2E1
shows a marginal activity toward VPA [42], it was used for
exploring the ligand orientation that is responsible of the low
activity of this isoform toward it. The C4 site has been pointed out
[9,11] as the site that undergoes site reaction mechanism, but
detailed binding orientations and interaction proﬁles between
these enzymes and VPA or 4nVPA were not reported until now.
Therefore, in order to evaluate the binding pose of VPA and 4nVPA
Fig. 6. The sequence alignment among chain A of ﬂurbiprofen-bound CYP2C9 (PDB code: 1R9O), CYP2C11 (Swiss-prot entry code: P08683), and chain A of omega-imidazolyl
octanoic acid-bound CYP2E1 (PDB code: 3KOH). The ﬁrst 29, 29, and 32 amino acids of these proteins, respectively, are not shown, and the amino acid sequence of chain B of
3KOH was deleted due to their identical amino acid composition to chain A. Conserved or highly conserved residues lining the substrate binding site are indicated by black
arrows, whereas the level of conservation is stressed by different colors. The sequence alignment was performed using PRALINE server [50].
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three CYPs. From this analysis, it was observed that both ligands
reached the substrate binding site which is formed by helices I, F, G,
loop F–G, and loop B–C (Fig. 2B), with the hydroxyl group (R–OH)
moiety oriented toward the heme and close to the iron (Fe) atom,
with an average distance of less than 4.0 A˚ (Fig. 2C–E). Our results,
demonstrated that the interactions coordinating the substrate are
predominantly hydrophobic as observed in some crystallographic
complexes. In Fig. 2C–E, it can be observed the residues within 4 A˚
involved in stabilizing the complexes where most of these residues
are making hydrophobic interactions through their side chains:
V113, A297, T301, L362, and L366 were establishing hydrophobic
interactions with the ligand in the CYP2C9–VPA and CYP2C9–
4nVPA complexes (Fig. 2C). The residues A297, G296, F205, T301, L361,
and V362 are the most involved in the CYP2C11–VPA and CYP2C11–
4nVPA complex (Fig. 2D). Otherwise, the residues I115, F116, F207,
A299, T303, V364, L368, and F478 are those that interact in the CYP2E1–
VPA and CYP2E1–4nVPA complexes (Fig. 2E). In overall, bothligands were positioned in essentially the same binding pose into
the three CYPs binding sites, even when some chemical differences
are present in both ligands.
Structural comparisons between the ligand orientation
obtained in this study through docking procedures and that
obtained using the same methodology to explore the dehydroge-
nation pathway of raloxifene [13], and even structural evidence of
some X-ray complexes, point out that the lowest energy cluster
predicted by Autodock for VPA or 4nVPA, produces a conformation
which could be described as a metabolically inactive state. In
contrast with our docking results, a metabolically active confor-
mation was reported for the 2C9–VPA complex using a methodol-
ogy that coupled the ROCS overlay method [69] and the docking
program FRED [70], in which the C4 atom was oriented toward the
FE atom [71]. Moreover, a MD simulation study on the picoseconds
time scale reported that VPA was coupled into the substrate
binding site of P450cam in a ligand conformation that oriented C4
toward FE atom, whereas that the carbonyl group stabilized
M. Bello et al. / Biochemical Pharmacology 90 (2014) 145–158152through electrostatic interactions [11]. On the other hand, it has
been stated that the bound pose with the lowest binding energy
does not correspond in most cases to the metabolically active
conformation [72], and that given the diverse nature of the
validation set of each docking program, it is expected that some
proteins will be easier to predict than others [73]. Besides, the
inclusion of ﬂexibility and water molecules in protein binding sites
also have important ramiﬁcations in docking poses of substrates in
the CYP active sites [72]. Therefore, MD simulations were
performed to reﬁne the map of interactions of VPA and 4nVPA
in the three CYPS, since that it has been reported that the fact of
including ﬂexibility to the docked conformation might reduce the
risk associated with inadequate ligand conformation [74].
3.3. Molecular dynamics (MD) simulations
The robustness and stability of the predicted 3D structures of
CYPs–VPA and CYPs–4nVPA complexes obtained using docking
methods were veriﬁed through MD simulations. Interestingly,
during the ﬁrst ns, all ligand conformations predicted by the
Autodock scoring function were lost and other conformations
present, where the aliphatic section of either VPA or 4nVPA was
oriented toward the heme group, were stabilized through
hydrophobic interactions, whereas the polar moiety was stabilized
by hydrogen bonds.
3.4. MD results
The robustness and stability of the predicted 3D structures of
CYPs–VPA and CYPs–4nVPA complexes obtained using docking
methods were further veriﬁed through MD simulations. Interest-
ingly, for all the cases, at ﬁrst ns the ligand conformations
predicted by Autodock scoring function were lost and other
conformations were present where the aliphatic section of either
VPA or 4nVPA was oriented toward the heme group, being
stabilized through hydrophobic interactions whereas the polar
moiety by hydrogen bonds.
According to the 50 ns MD simulation for the structure of CYPs
complexes, the RMSD for the a-carbon of CYPs as a function of the
simulation time became equilibrated for the last 40 ns, with RMSD
values that oscillated between 4.0 and 6.0 A˚ for all the complexes,
values in agreement with those observed for the MD simulation
studies between CYP2C9 and (S)-warfarin [75].
3.5. Interactional analysis and average properties
3.5.1. The case of CYP2C9
Structural analysis of different CYP complexes has allowed to
describe the different components of the substrate binding site,
which is mainly constituted by three parts: hydrophobic cleft that
consist of V113, L201, N204, I205, L208, V292, G296, A297, E300, and L366, a
ceiling which consist of the Phe cluster (F100, F114 and F476), and
narrow solvent channel residues (R108, and L102) (Fig. 3B). For the
CYP2C9–VPA complex was observed that at the ﬁrst ns of MD
simulations, the complex obtained through docking procedures
(see Section 2.2) changed, giving place to another conformation
where the polar interaction between the carboxylic moiety and the
heme group was lost (Figs. 2C and 3C). In this new conformation,
VPA packs next to helix I in a hydrophobic cleft that is formed by
V113, L201, N204, I205, L208, V292, G296, A297, E301, and L366, the Phe
cluster (F100, F114 and F476), and R108 (Fig. 3C), placing to VPA in
close proximity to the second most preferred channel named pw2e
[76] (Fig. 3B and C). Map of contacts that are in agreement with
those observed for the crystallographic complex between 2C9 and
ﬂurbiprofen (FLP) [77] (Fig. 3B). In this latter complex, FLP is
positioned with the site of hydroxylation located for oxidativeattack by the reactive, hypervalent iron-oxo intermediate derived
from reduction of molecular oxygen by the enzyme [77]. For VPA,
the aliphatic section was stabilized by several hydrophobic
residues and placing the site of dehydrogenation (C4 atom) resides
6.7 A˚ from the heme iron (Fig. 3C), which is consistent with the
distances seen in other CYP substrate complexes [77].
For the CYP2C9–4nVPA complex is observed that 4nVPA
preferred another conformation so different than that observed
for VPA, where the polar moiety was hydrogen bonding to N474 and
K206, whereas the aliphatic section was stabilized by several
hydrophobic contacts either backbone or side-chain atoms. This
ligand conformation shared few apolar contacts observed for VPA
and the site susceptible to undergo a dehydrogenation reaction
was localized in a farther distance (Fig. 3D). 4nVPA was located
between helices F and I and the turn in the C-terminal antiparallel
b-sheet. Interestingly, despite this region has been seen as a
narrow solvent channel (pw2c channel) formed by I205, S209, and
E300 and V479 in the crystal structure, this is only wide enough for
water molecules to enter, and catalogued as narrower than pw2e
channel [78]. MD simulations allowed to observe the increase of its
width, which was attributed to the backbone and side-chain
movements of I205 and S209 (mobile F helix) as well as side-chain
movements of E300 (stable I helix) because of their interactions
with the ligand [75], suggesting that the narrow channel might be
stabilized and widened in presence of substrate. Nevertheless, in
this study we did not observe signiﬁcant changes in the channel
width, which slightly opened with distances between 7.5 and
9.5 A˚.
3.5.2. The case of CYP2C11
Despite the lack of structural information about the CYP2C11
structure, some models have been constructed using molecular
modeling techniques and also coupled with organic molecules
such as testosterone [35]. From these studies, it is known that
ligands are mostly coordinated in the substrate-binding site of
CYP2C11, which includes a hydrophobic cleft constituted by I113,
T292, D293, G296, A297, E300, T301, and L366, a ceiling which consist of
the Phe cluster (F100, F114, F205, F208, F237, and F476) (Fig. 4B) [79].
From which, nine of these amino acid residues, namely F100, F114,
D293, G296, A297, E300, T301 L366, and F476 corresponded identically to
the key amino acid residues identiﬁed in the crystallographic
CYP2C9–FLP complex (1R9O), whereas that the Phe cluster at the
ceiling (F100, F114, F205, F208, F237, and F476) is similar to that of
human CYP3A4 [35]. On the other hand, as far as we are concerned,
until now there is not information about its solvent channels.
Therefore, in this study we evaluated the solvent channels for the
different complexes of CYP2C11–VPA or CYP2C11–4nVPA obtained
along the MD simulations using the MOLE program, which is
designed for channel identiﬁcation in macromolecules [80].
Derived from this latter analysis, several channels were found
which exhibited a bottleneck radii smaller than 1.4 A˚, which is the
radius of the water molecule. However, a channel constituted by
N202, P480, R307, T167, M198, F168, and H199 was found (data not
shown) in most of the complexes with a radii of 1.6–2.0 A˚, and with
bottleneck radii of 1.46 A˚, suggesting a possible pathway to the
entrance/exit of ligand, forming M198, and N202 the narrowest part
of the substrate access channel (Fig. 4B).
For the CYP2C11–VPA complex were observed four ligand
conformations along the 50-ns long MD simulations. At the ﬁrst ns
of MD simulations, the complex obtained through docking
procedures (see Section 2.2) changed as observed for CYP2C9–
VPA, giving place to a ligand conformation where the carboxylic
moiety established hydrogen bonds with R97 and a polar backbone
atom of F114, whereas the aliphatic chain was stabilized by several
members of the Phe cluster, as observed for other homology
modeling complexes [35]. This ligand conformation placed the C4
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present during the half of the MD simulations time (the ﬁrst 25-ns)
(Fig. 4C). After this time and until the 30-ns long MD simulation,
VPA was still coordinated by several members of the Phe cluster,
but the ligand adopted another conformations in which VPA was
basically coordinated by hydrophobic interactions (Fig. 4D and E)
and the closest C4 atom (C4 or C40) was into a atomic distance of 9.8
and 10.5 A˚, whereas that the keto group was stabilized by R97 and
looking toward the Fe atom into a distance of 9.0 A˚ (Fig. 4E). Then,
after this time and until the end of the MD simulation, VPA was
placed in another protein region close to the substrate binding site
and three Phe cluster members still made contacts with VPA
(Fig. 4F). Although the more representative ligand conformations
suggest that this ligand position could be consistent with that
required to experience a dehydrogenation reaction, the other
placed the ligand in a distance that would not allow the catalysis to
occur as proposed by several studies [81].
For the CYP2C11–4nVPA complex two conformations were
present, in the ﬁrst and the most representative conformation of
4nVPA (Fig. 4G, 10 to 45 ns), this was coordinated by a number of
residues also present in the CYP2C11–VPA complex (Fig. 4C–F and
G–H). In this ligand conformation, only a residue that belongs to
the Phe cluster was observed (F476), whereas the keto group
formed a salt bridge with R97, in a similar manner to that observed
for CYP2C11–VPA (Fig. 4C). In contrast, the second conformation
(Fig. 4H, 45 to 50 ns) was mostly stabilized by a member of the Phe
cluster but by a less energetically optimized salt bridge between
the keto group and R97. Nevertheless, both ligand conﬁgurations
placed the reduced C4 atom (C4n) into a similar distance from the
Fe atom, shorter distance than that observed for VPA, suggesting
that the reduced metabolite could be able to experience a further
catalysis reaction (Fig. 4G–H).
3.5.3. The case of CYP2E1
CYP2E1 catalyzes oxidative reaction of not only low molecular
weight xenobiotic compounds such as ethanol, but also endoge-
nous fatty acids [82]. In contrast with CYP2C11 and CYP2C9 whose
cavities are wide enough to accept bulky ligands, CYP2E1 is
characterized by catalyzing small weight compounds and large
fatty acids [82] and its active site size is considered as the smallest
(200 A˚3) among human CYPs [83]. The structural feature might
be responsible for the advantageous of CYP2E1 over the others
CYPs to metabolize small weight compounds, then creating
speculation about whether the pathways in CYP2E1 will differ
from those found in other mammalian CYPs [82]. In the course of
multiple co-crystallized complexes, it has been elucidated that as
observed for CYP2C9 and CYP2C11 complexes, several conserved
residues lining a hydrophobic cleft participate in the complex
stabilization: I115, E302, A299, L363, V364, and, L368. The Phe-cluster is
also present, including to F106, F116, F207, F298, and F478, which forms
a ceiling on the binding pocket and blocked the channel 2c [82], as
well as T303 which is localized in helix I and plays an important role
in the substrate recognizing and positioning by establishing
hydrogen bonds with the substrate in the active site [84], whereas
that V364 and F478 form the narrowest part of the substrate access
channel, allowing substrate or solvent entering into or release [84]
(Fig. 5B). Furthermore, punctual mutations over residues such as
F478V showed to increase 7-ethoxy-4-triﬂuoromethylcoumarin
deethylation activity but lower p-nitrophenol hydroxylation
activity than wild type CYP2E1, indicating that these residues
are important for the speciﬁcity of this isoform [85]. Although it
has been reported a minimal inhibition activity of VPA on CYP2E1,
the ligand orientation of VPA was explored to gain insight about
this behavior [42].
At the beginning of the simulation, the ligand conformation
presented in the docked CYP2E1–VPA complex (Fig. 2E) was lost asobserved for the CYP2C9–VPA and CYP2C11–VPA complexes,
giving place to three energetically allowed states where the two
ﬁrst states were present during the three ﬁrst ns and the third
state started after 3 ns time and lasted almost during all the MD
simulation. From Fig. 5C–E, it can be observed that VPA was
mostly coordinated by residues that belong to the Phe cluster
(F106, F116, F207, F298, and F478), which has been reported as
important in the stabilization of some complexes obtained
through crystallographic procedures [81,82] and also using MD
simulations [84] whereas the polar group was forming salt bridges
either with N206 or H109 or simultaneously with both residues.
Interestingly, T303 has been observed to play an important role in
stabilizing and positioning the ligand through its interaction by a
hydrogen bond [84]. In contrast, for the case of VPA, is observed
that one of the residues that stabilize the polar group was N206,
which also is seen to establish a hydrogen bond with the ligand in
the co-crystallized complex between CYP2E1 and the omega-
imidazolyl octanoic acid [83]. Furthermore, as observed for the
CYP2C9 and CYP2C11 complexes, a cluster of Phe also was
involved in stabilizing the VPA molecule. However, in contrast
with the favorable ligand conformations showed by CYP2C9 and
CYP2C11 complexes, the three ligand conformations present here,
did not produce a ligand orientation that could be able to
participate in an oxide-reduction reaction, since both C4 atoms
were positioned into a distance between 8.0 and 10.0 A˚ from Fe
atom, distance slightly higher in comparison with that reported
for some static complexes [84] and another gotten through MD
simulations [85].
For the CYP2E1–4nVPA complex was found that two states were
experienced by 4nVPA into the substrate-binding site. Fig. 5F–G
shows that 4nVPA was coordinated by almost the same type of
residues than for CYP2E1–VPA. However, 4nVPA adopted another
position that allowed it to establish a closer contact between C4
and the Fe atom, suggesting that perhaps this enzyme possess a
higher afﬁnity for the reduced metabolite rather than the native
molecule.
3.6. Calculation of the binding free energy for the CYP’s-ligand
complexes
To gain more information about the energetic contribution
between the residues surrounding the binding site and the ligand,
the electrostatic energies, non-polar solvatation, Van der Waals
interactions and total contribution of the residues to the binding
free energy were calculated with the molecular mechanics
generalized born surface area (MM-GBSA) method [86,87] (see
Section 2). This analysis shows that the complex formation is
mainly driven by the non-polar (DEvwd + DGnpol,sol) contributions,
being DEvwd interactions those that make the major contribution,
whereas that the polar (DEele + DGele,sol) interactions contributed
scarcely or opposed to the binding (Table 1). Thermodynamic
behavior that is supported by the map of interactions observed for
each of the representative VPA and 4nVPA binding models, where
is visualized that all the complexes are mainly stabilized through
hydrophobic interactions (Fig. 7). The calculated binding free
energy (DGbind) was more energetically favorable for the
complexes formed between CYP2C9, CYP2C11 or CYP2E1 and
VPA, being the highest for the CYP2C11–VPA complex (CYP2C11–
VPAc). In contrast, all the complexes between the three CYPs and
4nVPA produced smaller binding free energies and even
unfavorable were observed for the CYP2C11–4nVPA complex.
The entropic component was consistent among all the complexes,
revealing that upon complex formation a decrement in their
degrees of freedom is present which contributes with an
unfavorable entropy component to the calculated binding free
energy.
Table 1
Binding free energy components of CYP’s-ligand complexes (in units of kcal/mol).
System DEvdw DEele DGele,sol DGnpol,sol DEpolar DEnpol DGmmgbsa T DS DGbind
CYP2C9–VPA 17.0 (0.15) 242.3 (1.3) 240.5 (1.2) 2.65 (0.02) 1.80 19.65 21.45 (0.2) 16.40 (3.0) 5.05
CYP2C9–4nVPA 18.90 (0.15) 203.0 (0.72) 206.3 (0.6) 3.31 (0.01) 3.30 22.21 18.91 (0.20) 15.36 (1.4) 3.55
CYP2C11–VPAc 21.0 (0.23) 255.0 (1.1) 256.34 (0.91) 3.24 (0.01) 1.40 24.24 22.84 (0.3) 15.91 (1.15) 6.93
CYP2C11–VPAde 18.95 (0.10) 200.0 (0.7) 206.0 (0.51) 2.74 (0.01) 6.0 21.69 15.69 (0.15) 16.64 (2.10) +0.95
CYP2C11–VPAf 16.24 (0.10) 177.4 (0.40) 187.0 (0.40) 2.20 (0.01) 9.6 18.44 8.84 (0.10) 17.11 (1.6) +8.27
CYP2C11–4nVPA 12.1 (0.7) 153.0 (10.1) 157.0 (10.2) 2.01 (0.10) 4.0 14.2 10.2  0.73 19.0  4.21 +8.80
CYP2E1VPA 19.0 (0.3) 351.0 (4.0) 348.0 (4.0) 3.20 (0.04) 3.0 22.2 25.0  0.35 19.60  2.75 5.40
CYP2E14nVPA 16.6 (0.12) 337.0 (0.66) 343.0 (0.58) 2.77 (0.01) 6.0 19.37 13.37 (0.15) 12.20  5.73 1.17
The polar (DEele + DGele,sol) contributions (DEpolar) and the non-polar (DEvwd + DGnpol,sol) contributions (DEnpol). All the energies are averaged over several snapshots (see
Section 2) and are in kcal/mol (standard error of the mean).
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In silico methods have been widely used to investigate
important features of CYPs, and particularly focused on the
CYP2C9 active site [85,88,89] with the aim to predict positions of
oxidation and determine important structural features that confer
selectivity. Initially, because of the lack of structural information,
CYPs structures were obtained through homology modeling
procedures. Nowadays the availableness of several structures of
CYPs has been so useful to further improve our knowledge about
the ligand recognition between several organic molecules and
CYPs molecules. Among these structures, CYP2C9 was one of the
ﬁrst structures released in the PDB forming complex with warfarin
(PDB entry, 1OG5), although this complex showed an unproductive
ligand conformation because the substrate lies in a mostly
hydrophobic cavity at a distance of 10 A˚ from the heme unit
[71]. MD simulation allowed to explore several ligand conforma-
tions in which warfarin was positioned in a favorable distance as to
undergo a 6-7-hydroxylation [75], with a marked geometrical
preference for position 7 over position 6 and also with an
important structural contribution of F476. Furthermore, analysis of
the substrate cavity of CYP2C9 (470 A˚3) and NMR studies indicated
that this isoform is able to bind two different ligands simulta-
neously [90]. Later on, other crystal structure of CYP2C9 was
published with FLP bound (PDB entry, 1R9O), which is known to
undergo oxidation, primarily by 40-hydroxylation. For this
complex, in contrast with that observed in the 1OG5 structure,
the 40-oxidation site was within an appropriate distance for
oxidative attack by the reactive hypervalent iron-oxo intermediate
derived from the reduction of molecular oxygen by CYP2C9.
Substrate-heme distance that is in agreement with that observed
through NMR studies was between 3.3 and 6.2 A˚ [91]. The lack of
3D information of several complexes between CYPs and some
molecules for which experimental evidence about their hydroxyl-
ation or dehydrogenation has been observed, has led to choose
some computational approaches, such as docking procedures to
gain insight into the reaction mechanism [13,36]. However, this
method is limited to some extend by poor contribution of the
protein ﬂexibility and some other factors [38]. Therefore,
molecular docking and molecular simulation have been combined
to tackle the environment problems including oxidative polymeri-
zation of alkyl phenols [92], but up to date a combined approach of
these two methods to model CYPs has not been used. To address
this issue, we performed molecular docking and MD simulations
using available structural information (CYP2C9 and CYP2E1) and
also homology modeling techniques (CYP2C11) to obtain our
proteins, which then were coupled though docking procedures and
simulated for 50 ns using MD simulations. Our docking results
revealed that a common ligand conformation into the binding site
of the three CYPs was present for both VPA and its reduced
metabolite 4nVPA, in which the polar moiety was making
interaction with the heme group into a distance of 4 A˚, whereasthat the potentially place to experience an electrophilic attack was
in a opposed orientation to the center ferric atom of the heme
group. This conformation was modiﬁed at ﬁrst ns of MD
simulations, leading to a range of energetically accessible ligand
conformations for the three CYPs. For all the systems was observed
that the aliphatic section of VPA was stabilized by hydrophobic
residues, but for CYP2C11 and CYP2E1 a higher number of Phe
residues was seen coordinating the VPA than for CYP2C9, whereas
the polar moiety was hydrogen bonding to polar residues and for
most the residues observed stabilizing these complexes there is
structural evidence [35,77]. DGbind values were more energetically
favorable for the complexes formed between CYP2C9, CYP2C11 or
CYP2E1 and VPA than for 4nVPA, corroborating the expected high
afﬁnity for VPA than for the reduced metabolite.
For the CYP2C9–VPA complex only one VPA conformation was
present in which the closest C4 atom was positioned into an atomic
distance (6.7 A˚) for electrophilic attack, which is consistent with
the distances seen in other CYP2C9 substrate complexes [77]. In
contrast, for the CYP2C9–4nVPA complex, 4nVPA adopted another
conformation so different than that observed for VPA, in which was
located in close proximity to a water channel observed through MD
simulations [75]. The susceptible site (C4 atom) to undergo a
second dehydrogenation reaction was localized in a farther
distance than for VPA. Both results are characteristic of an inactive
substrate that is being expelled out of the catalytic binding site.
Four ligand states were present for VPA in the CYP2C11–VPA
complex where the most predominantly VPA conformation
placed the closest C4 atom into a distance of 7.0 A˚ from Fe atom,
distance consistent with that required to experience a dehydro-
genation reaction, whereas the other three remaining states
would not allow the catalysis to occur as proposed by several
studies [81]. For the CYP2C11–4nVPA complex two states were
present from which the most representative 4nVPA conformation
placed the reduced C4 atom (C4n) into a similar distance from the
Fe atom, in a shorter distance than that observed for VPA,
suggesting that the reduced metabolite could be able to
experience a further catalysis reaction.
For the CYP2E1–VPA complex three energetically states were
present where the most representative state did not produce a
ligand orientation that could be able to participate in an oxide-
reduction reaction, since both C4 atoms were positioned into a
distance between 8 and 10.0 A˚ from Fe atom, distance slightly
higher in comparison with that reported for some static complexes
[81] and another observed through MD simulations [82].
Therefore, this less favored ligand conformation could be
responsible for the minimal inhibition activity experimentally
reported for this human CYP isoform [42]. For the 2E1-4nVPA
complex, two 4nVPA states were present into the substrate-
binding site adopted a ligand position that would allow it to
establish a closer contact between C4 and the Fe atom, suggesting
that perhaps this enzyme possess a higher afﬁnity for the reduced
metabolite rather than the native molecule.
Fig. 7. Schematic representations of hydrogen bonds (green dashed lines) and hydrophobic contacts (red arc with spokes) of CYP2C9–VPA (2SA), CYP2C9–4nVPA (2SB),
CYP2C11–VPA (2SC-F), CYP2C11–4nVPA (2SG and H), CYP2E1–VPA (2SI-K), and CYP2E1–4nVPA (2SL and M) complexes. Drawings were generated using LIGPLOT v.4.5.3 [94],
and the average conformations from Figs. 3C and D, 4C–H, and 5C–G.
M. Bello et al. / Biochemical Pharmacology 90 (2014) 145–158 155The multiple ligand conformations present for CYP2C11 and
CYP2E1 suggest a high ﬂexibility into the catalytic binding site that
could work as an adaptative mechanism to place the substrate
through subtle conformational changes that contribute to get morefavorable energetic states. Furthermore, the presence of multiple
binding orientations may give place for the production of multiple
oxidized metabolites as observed for the case of hydroxylation of
progesterone into the catalytic binding site of CYP2C5 [93].
M. Bello et al. / Biochemical Pharmacology 90 (2014) 145–158156Based on these results, it is clear that geometrical preference
is regulated by the chemical nature of the substrate, the
substrate binding cavity and the ﬂexibility of the residues
constituting the catalytic binding site. Therefore, the regios-
electivity is a result of the chemical and shape of the protein and
ligand rather than caused by local interaction near the heme
oxygen as mentioned by Seifer et al. [75]. Furthermore, our
results have important contribution to the details of enzyme-
catalyzed reactions in the process of VPA dehydrogenation,
which can broaden our knowledge of this reaction mechanism.
However, in contrast to soluble bacterial CYPs, mammalian CYPs
are membrane-anchor proteins bound to a lipid membrane
through the N-terminal transmembrane helix, so the ligand
conformation observed here may be improved in a more
physiological system.
In conclusion, docking and MD simulation studies were
performed to gain insight into the regioselectivity of VPA into
three CYPs for which it is known to exhibit afﬁnity. Our results
showed VPA states into the CYP catalytic cavity of CYP2C9 and
CYP2C11 where C4 was oriented toward the Fe atom for
electrophilic attack and therefore experiences a dehydrogenation
reaction, but a less favored C4 position was observed for CYP2E1,
corroborating the lower afﬁnity reported from this CYP to VPA. On
the other hand, 4nVPA showed some differences with respect to its
placing into the three CYPs. For the CYP2C9–4nVPA complex,
4nVPA not only showed a less optimized map of interactions, result
that was in agreement with its unfavorable DGbind value, but also
was collocated close to a water channel, suggesting that 4nVPA is
not candidate to experience further catalytic reaction in this CYP
and that maybe is being expelled from the catalytic binding site. In
contrast, for the CYP2C11–4nVPA and CYP2E1–4nVPA complexes,
4nVPA showed states that suggest further catalytic reactions
because of its shorter distance to the Fe atom in comparison with
the observed for VPA. However, binding free energy analysis
showed unfavorable and marginal favorable DGbind values for
CYP2C11–4nVPA and CYP2E1–4nVPA complexes, suggesting that
these states could correspond to energetic transient states. Overall,
these results show that not only the chemical nature of the CYPs
cavity and its intrinsic ﬂexibility play an important role in ligand
stabilizing and positioning, but also the chemical structure may
have critical structural effect on the binding pose of the ligand,
promoting ligand orientation toward heme group in the three
CYPs.
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